Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nuclear receptors: decoding metabolic disease.

Junichiro Sonoda1, Liming Pei, Ronald M Evans

  • 1Howard Hughes Medical Institute, The Salk Institute for Biological Studies, 10010N. Torrey Pines Road, La Jolla, CA 92037, USA.

FEBS Letters
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis.

Cell stem cell·2026
Same author

HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Mitochondrial cardiomyopathy: bridging molecular mechanisms and clinical frontiers.

Nature reviews. Cardiology·2026
Same author

A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer.

The oncologist·2026
Same author

HDAC INHIBITION SENSITIZES PANCREATIC TUMORS TO DNA DAMAGE BY GLOBAL REDISTRIBUTION OF THE TRANSCRIPTIONAL MACHINERY.

bioRxiv : the preprint server for biology·2026
Same author

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

Nature cancer·2026
Same journal

Extending the classical sequence-structure-function paradigm through protein dynamics and context-dependent behavior.

FEBS letters·2026
Same journal

α-Synuclein aggregation landscape from phase separation to neurotoxic intermediates.

FEBS letters·2026
Same journal

Modelling stem cell differentiation related processes-A practical overview for biologists.

FEBS letters·2026
Same journal

Overlapping gut microbiome signatures in aging and disease are characterized by enrichment of medication-associated oral microbes in the gut.

FEBS letters·2026
Same journal

Csk binding to integrin β3 is regulated by tyrosine and threonine phosphorylation of β3.

FEBS letters·2026
Same journal

Mixed-class J-domain protein scaffolds promote expanded aggregate handling and multivalent Hsp70 engagement during functional disaggregase assembly.

FEBS letters·2026
See all related articles

Nuclear receptors (NRs) are crucial proteins regulating metabolism. Understanding these complex NR metabolic networks is vital for developing treatments for metabolic diseases like diabetes and dyslipidemia.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Nuclear receptors (NRs) are ligand-activated transcription factors.
  • NRs regulate critical physiological processes including development, reproduction, and metabolism of lipids, drugs, and energy.
  • Dysregulation of NR activity is implicated in various metabolic disorders.

Purpose of the Study:

  • To summarize current knowledge on the complex metabolic networks regulated by nuclear receptors.
  • To highlight the therapeutic potential of NR ligands in metabolic diseases.

Main Methods:

  • Review of existing literature on nuclear receptors and metabolic regulation.
  • Analysis of genetic studies in humans and rodents.
  • Compilation of information on NR ligands in clinical and exploratory development.

Related Experiment Videos

Main Results:

  • NRs control a wide array of metabolic processes.
  • NRs regulate gene expression of key metabolic enzymes, transporters, and proteins.
  • NR ligands are established or emerging treatments for diabetes mellitus, dyslipidemia, and hypercholesterolemia.

Conclusions:

  • Nuclear receptors play a central role in maintaining metabolic homeostasis.
  • Targeting NR pathways offers significant therapeutic opportunities for metabolic diseases.
  • Further research into NR metabolic networks can lead to novel treatment strategies.